SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

Thrombocytopaenia Clinical Trial

Official title:
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy

Status Completed

Clinical Trial Summary

SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with advanced solid tumors scheduled to receive chemotherapy with carboplatin and paclitaxel every 21 days. Patients will receive SB497115 on days 2-11 of each 21 day cycle for at least 2 cycles of chemotherapy and for a maximum of 8 cycles of chemotherapy.

Clinical Trial Description

A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00102726
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	February 2005
Completion date	February 2007

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01440374` - A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia	Phase 2
Completed	`NCT01957176` - A Rollover Study to Provide Continued Treatment With Eltrombopag	Phase 4
Withdrawn	`NCT01055600` - Milk-only Lactation Study for Patients on Eltrombopag	Phase 4
Completed	`NCT01147809` - Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag	Phase 2
Terminated	`NCT02158936` - A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)	Phase 3
Completed	`NCT00358540` - Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide	Phase 1
Completed	`NCT01235988` - Meta-analysis - Eltrombopag	N/A
Completed	`NCT01236014` - Indirect Comparison Between Eltrombopag & Romiplostim	N/A
Completed	`NCT01657552` - Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects	Phase 1